Meeting Solid Dose Formulation Challenges

Similar documents
Application of Quality by Design (QbD) in product development. James E. Polli September 16, 2015

How to Identify Critical Quality Attributes and Critical Process Parameters

Implementing Quality by Design Principles and Concepts to Drug Delivery and Formulation Development. S Betterman 15Apr2015

Balancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL

Quality by Design for ANDAs: An Example for Immediate-Release Dosage Forms

METHOCEL. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow

QbD implementation in Generic Industry: Overview and Case-Study

Scientific and Regulatory challenges in Quality by Design (QbD) submissions

PHARMACEUTICAL MANUFACTURING

CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE

QbD (Quality by Design) Has industry benefited from this? WHITE PAPER.

BEAM ASPECTS OF COMPOUNDING PRODUCT DESIGN. Reinout C.A. Schellekens, PharmD, RHPh, QP. Head Clinical Drug Production and Development

Quality by Design (QbD) : A new concept for development of quality pharmaceuticals

WHITE PAPER: Amorphous Solid Dispersions-One approach to improving Bioavailability

Full Length Original Research Paper

Formulation Development

Analytical and formulation attributes

QbD In Drug Development. Mathew Cherian Ph.D. Director & Senior Fellow Pfizer, USA

Guidance for Industry

Roller Compaction: New trends, challenges and solutions

QbD and the New Process Validation Guidance

"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY

CMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C.

DECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE

Evolution of the CMC Review - ANDAs

Review Article Review on Quality by Designing for Metered Dose Inhaler Product Development Santosh R. Thorat * 1, Sarika M.

Evolution of Quality Assessments Recent Trends in FDA Queries. Mike Saleh, Pfizer Inc.

Pharma & Food Solutions. ETHOCEL One of the Few Water-Insoluble Polymers Approved for Global Pharmaceutical Applications

GUIDELINE FOR THE STABILITY TESTING

Implementation of PAT for Real Time Release Testing. Mark Smith Process Analytical Sciences Group Pfizer, Cork

Regulatory Assessment

Agilent TRS100 Raman. Quantitative Pharmaceutical Analysis System

STIMULI TO THE REVISION PROCESS

Kollidon The Original Setting new standards in stability, purity and patient safety.

Design and Dosage Form. Dr. Deny Susanti

Roller compactors for the pharmaceutical industry. BT 120 Pharma WP 120 Pharma WP 150 Pharma WP 200 Pharma

Experimental design on product development

R&D TO PRODUCT: HOW TO REDUCE COSTLY SCALE-UP PROBLEMS

Approaches to the formulation of poorly soluble drugs

SUPAC OF IMMEDIATE-RELEASE, MODIFIED- RELEASE AND SEMI-SOLID: A REGULATORY NOTE

Management Team. Over 35 years experience in the pharmaceuticals industry

Cocrystals: A Regulatory Perspective. Scott L. Childs Renovo Research

RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products

Pelagia Research Library

Industry Perspective on Manufacturing in Early Development

Oral Dosage Formulation Development

Microcrystalline Cellulose, Colloidal Silicon Dioxide, Sodium Starch Glycolate, Sodium Stearyl Fumarate

Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza

Early Development Best Practices for Stability- Regulatory Perspective

Pharmaceutical Sciences

PLANKSTADT EXPERTS TAKING CARE

Maximizing Roller Compaction Benefits with Proper Excipient Selection

The Emerging Technology Program: FDA s Perspective

How Research Can Help Us Rethink Lifecycle Management and Post- Approval Changes: Oral Products

A Science Based Approach for Topical Drug Classification System

Clinically Relevant Dissolution Specifications: FDA Perspective and Initiatives

Short review on Quality by design: A new Era of Pharmaceutical drug development

Risk Management in Drug Product Manufacturing with Emphasis on Batch Documentation/Execution

Application of Quality by Design in formulation and process Development

ANDA FILING CHECKLIST (CTD or ectd FORMAT) FOR COMPLETENESS AND ACCEPTABILITY of an APPLICATION


Quality by Design Specifications for Solid Oral Dosage Forms: Multivariate Product and Process Monitoring for Managing Drug Quality Attributes

Biowaivers and Harmonization Guidelines for Class I and 3 Drugs: Biowaiver Case Studies

GUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs)

Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation

Strategic Implantation of PAT : FDA Perspective

Performance Testing of Novel Dosage Forms

Association. Case Study 3. achieving real time release testing by a

Successful Tableting Supplement. Continuous Tableting MODUL Q A-Type Tooling. engineering for a better world

Development of paediatric formulations - points to consider

Research Article. Quality by Design (QbD) Approach for Formulation Development of Hydralazine Hydrochloride Tablets

Current Features of USFDA and EMA Process Validation Guidance

International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW

ANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS

Product Questionnaire

Setting Specifications

Flexible and Pending Monographs

PMDA Views on Applying Continuous Manufacturing to Pharmaceutical Products for Industry (provisional draft)

EMCOMPRESS. Calcium Hydrogen Phosphate, Ph.Eur., E 341(ii) Dibasic Calcium Phosphate, USP/NF, FCC. A Proven Excipient for more than 60 Years

Solid Phase transformation considerations during process development and manufacture of solid oral dosage forms A Review

Excipient Development at NCL

Glossary of Abbreviations

GDUFA RESEARCH AND REGULATORY INITIATIVES FOR COMPLEX TOPICAL PRODUCTS

Identification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study

Streamlining Development and Approval Processes for 505(B)(2) NDAs

SCIENTIFIC DISCUSSION

Formulation and in vitro evaluation of bosentan osmatic controlled release tablets

ANDA FILING CHECKLIST (CTD or ectd FORMAT) FOR COMPLETENESS AND ACCEPTABILITY of an APPLICATION

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

BMS Experience with the FDA-EMA QbD/PAT Joint Pilot Ambarish K. Singh, PhD Director, Global Regulatory Sciences-CMC Bristol-Myers Squibb Company

O RAL. Tablets HANDBOOK OF PHARMACEUTICAL VOLUME I - Part ONE. Immediate Release GENERIC DEVELOPMENT

Biowaiver Approaches for Generic Drug Products in the US: Case Studies

Application Strategy of PBPK for Generic Drugs and Its Current Challenges

Complexity of Retention Samples Selection in non-traditional Bioequivalence studies

Analysis of Non-Pivotal Bioequivalence Studies Submitted in Abbreviated New Drug Submissions for Delayed-Release Drug Products

Continuous Manufacturing: An Industry View

Recent FDA Guidance For Industry; BCS Class 1 and 3 August 2015

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2

CGMP Requirements for Investigational Products

O RAL C. apsules HANDBOOK OF PHARMACEUTICAL GENERIC DEVELOPMENT. VOLUME II - PART ONE Drug Development - Solid Oral Dosage Forms.

Transcription:

Streamlining (Fast Tracking) Solid Dosage Form Development Tony Carpanzano, B.S., R. Ph. Director, Research & Development Streamlining (Fast Tracking) Solid Dosage Form Development Meeting Solid Dose Formulation Challenges

New Development Project UPPER MANAGEMENT: Here s your challenge.. I want it done fast, I want it done right, and I want it at low cost! New Development Project UPPER MANAGEMENT: Here s your challenge.. I want it done fast, I want it done right, and I want it at low cost! Experienced Formulator:.. You can have any two options..

Best Response Focusing attention to several key points in formulation development will aid in Fast tracking a product, keeping costs to a minimum, and establish a solid foundation for fulfilling regulatory requirements (QBD). Seven Basic Habits of Highly Effective Be Proactive Begin with the end in mind Put first things first Think win-win Synergize Sharpen the saw

Seven Basic Habits of Highly Effective Be Proactive Systematic Approach Begin with the end in mind Put first things first Think win-win Synergize Sharpen the saw Seven Basic Habits of Highly Effective Be Proactive Systematic Approach Begin with the end in mind Pre-defined objectives Put first things first Think win-win Synergize Sharpen the saw

Seven Basic Habits of Highly Effective Be Proactive Systematic Approach Begin with the end in mind Pre-defined objectives Put first things first Product & Process Think win-win Synergize Sharpen the saw Seven Basic Habits of Highly Effective Be Proactive Systematic Approach Begin with the end in mind Pre-defined objectives Put first things first Product & Process Think win-win Process Control Synergize Sharpen the saw

Seven Basic Habits of Highly Effective Be Proactive Systematic Approach Begin with the end in mind Pre-defined objectives Put first things first Product & Process Think win-win Process Control Good science and quality risk management Synergize Sharpen the saw Seven Basic Habits of Highly Effective Be Proactive Systematic Approach Begin with the end in mind Pre-defined objectives Put first things first Product & Process Think win-win Process Control Good science and quality risk management Synergize Production efficiency, post launch mgmt. Sharpen the saw Continual improvement

Solid Dose Formulation Challenges Solid Dose Formulation Challenges Formulation and Manufacturing process NDA Innovator has a high degree of freedom ANDA Generic companies have a much lesser degree of freedom Regulatory / compendial issues Cost issues Patent / legal issues QBD FDA requirements have mandated a more comprehensive (exhaustive) development process Data driven formulation and process selection Burden? Opportunity? Advantage?

Solid Dose Formulation Challenges - API Physical form Crystalline, amorphous, polymorphic (patented?) Oil, waxy, or low melting solid Cohesive requires high energy input to disperse and achieve uniformity may stick to punches Poor flow may lead to poor weight/hardness/content uniformity Low density Fluffy, fly-away, difficult to handle safety Solid Dose Formulation Challenges - API Not compressible May require extensive processing and/or large amounts of excipients to form a tablet Solubility High solubility not usually an issue for IR, but can be an issue for ER Low solubility generally an issue Hygroscopic Unstable Sensitive to moisture, heat, light, oxygen or other components

Solid Dose Formulation Challenges Dosage Form Dosage form Tablet (IR, MR, fast dissolve), capsule or soft gel Therapeutic Dosage level High dose tablet size try to keep excipient levels as low as possible need high functionality Low dose uniformity typically wet granulation is the process of choice, high functionality excipients offer alternatives Compatibility of needed excipients with API Binders, diluents, Coatings functional or cosmetic Key Points for Development

The Fast Track Target product profile Clearly defined expectations SMART Literature search Patents can help or be misleading Related compounds and drug products Chemistry, PDR Unusual or proprietary excipients The Fast Track Pre-Formulation do the homework Characterize the API Risk Assessments for API attributes on drug product CQA s Characterize the Reference Label Drug (generics) Reverse engineering Formulation Gain insight to process Have a thorough understanding of the proposed excipients functionalities and limitations

The Fast Track Excipient selection Understand stability impact Known API interactions and incompatibilities Rationale for excipient selection RLD (generics) QBD Risk assessment for selected excipients Functionality or data driven Process Selection The Fast Track Understand stability impact Process conditions to avoid (heat, moisture, shear, atmosphere) Rationale for process selection RLD (generics) QBD Risk assessment for selected process Functionality or data driven

The Fast Track Initial Formulation Prototypes Physical characterization In-vitro characterization Microbiological evaluation Accelerated stability Pilot-Bio study Stability in proposed commercial packaging Updated risk assessment for formulation The Fast Track Prototype Process Evaluate & identify key processing steps Conduct pilot-scale studies Propose PAT where appropriate Updated risk assessment for process

The Fast Track Scale-up / Commercial Process Assessment of key process steps Evaluate PAT where appropriate Define process control strategy Updated risk assessment Packaging Stability of commercial package(s) Post launch product lifecycle management PAT data, yield analysis Continual improvement QUESTIONS